Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual-targeting VEGFR1 and PD-L1 CAR-T Cells in Solid Tumors With Serosal or Leptomeningeal Metastases
NCT05477927Phase 1Recruiting
- Sponsor
- Sichuan University
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in malignant ascites, Serous cavity metastasis and leptomeningeal metastases (LM), sponsored by Sichuan University. Primary endpoints: Adverse Events and Serious Adverse Events at 6 months, Dose-Limiting Toxicity at 21 days and 1 more. Started Feb 2023; status: recruiting.
02
Conditions
malignant ascitesSerous cavity metastasisleptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT05477927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05477927.